BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27021085)

  • 1. Chromogranin As a Biochemical Marker of Neuroendocrine Tumors.
    Lyubimova NV; Churikova TK; Kushlinskii NE
    Bull Exp Biol Med; 2016 Mar; 160(5):702-4. PubMed ID: 27021085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute.
    Jun E; Kim SC; Song KB; Hwang DW; Lee JH; Shin SH; Hong SM; Park KM; Lee YJ
    Surgery; 2017 Jul; 162(1):120-130. PubMed ID: 28262254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
    Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
    Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
    Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
    Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
    Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
    J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
    Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
    Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript.
    Bech PR; Ramachandran R; Dhillo WS; Martin NM; Bloom SR
    Clin Chem; 2012 May; 58(5):941-3. PubMed ID: 22361937
    [No Abstract]   [Full Text] [Related]  

  • 10. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
    Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
    Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
    [No Abstract]   [Full Text] [Related]  

  • 11. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
    Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F
    Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical evaluation of a second generation assay for chromogranin A; a dual-site study.
    Krabbe JG; Monaghan PJ; Russell J; de Rijke YB
    Clin Chem Lab Med; 2016 Apr; 54(4):e139-42. PubMed ID: 26393331
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
    Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
    Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results].
    Glinicki P; Jeske W
    Endokrynol Pol; 2009; 60(5):415-9. PubMed ID: 19885814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
    Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.
    Miki M; Ito T; Hijioka M; Lee L; Yasunaga K; Ueda K; Fujiyama T; Tachibana Y; Kawabe K; Jensen RT; Ogawa Y
    Jpn J Clin Oncol; 2017 Jun; 47(6):520-528. PubMed ID: 28334992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.
    Hong L; Wang Y; Zhang T; Zhang C; Wang L; Wang L; Wang Z; Zhong J
    Med Sci Monit; 2020 Nov; 26():e926635. PubMed ID: 33141811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis.
    Rossi RE; Ciafardini C; Sciola V; Conte D; Massironi S
    Pancreas; 2018; 47(10):1249-1255. PubMed ID: 30325865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromogranin A: is it a useful marker of neuroendocrine tumors?
    Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
    J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
    Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.